Dan Strange

Chief Technology Officer • Cellular Origins, A TTP Company

For 15 years, Dan has worked at the intersection of engineering and biology. Dan carried out his PhD at Cambridge University, designing and automating tissue engineering bioprocesses. He then moved to TTP where he worked with clients to invent, design, and develop medical devices for clients such as 3M and Allergan before joining TTP’s cell and gene group to focus on automation, tools and technologies for cell therapy manufacturing. He has been involved in the development of 5 modular manufacturing systems ranging from cell selection to expansion. Dan is an active member of various automation working groups and a founding member of the TTP Cambridge Cell and Gene community. He is passionate about finding solutions to scale cell therapy to the hundreds of thousands of patients that could benefit. 

Also Speaking

Samik Upadhaya

Assistant Director of Scientific Affairs • Cancer Research Institute

Michael Von Forstner

Global Head of Clinical Safety and Pharmacovigilance • Biogen

Sumit Verma

Senior Vice President, Commercial Manufacturing • Iovance Biotherapeutics Inc

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.